News | Left Atrial Appendage (LAA) Occluders | April 25, 2017

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

AtriClip franchise expanded to include AtriClip PRO2 device in 2016

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

April 25, 2017 — AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide. This makes it the most widely used of all devices for excluding the left atrial appendage (LAA), according to the company.

The LAA is a muscular pouch attached to the heart’s left atrium. In patients with atrial fibrillation (Afib) and other cardiac arrhythmias, blood can pool and form clots in the appendage, which may then leave the heart and cause strokes. One study concluded that more than 90 percent of detected blood clots in patients with atrial fibrillation are formed in the LAA.1

Patients who suffer from Afib have a 500 percent greater risk of stroke, compared with the general population.2 Afib-related strokes are associated with higher morbidity and mortality than non-Afib related strokes.3 Prior to the invention of the AtriClip system, cardiac surgeons typically addressed the LAA during open heart surgery by cutting it off or closing off the opening of LAA to the atrium. This approach required extra time on the heart-lung machine and posed a risk of hemorrhaging and or reopening over time.

Since the launch of the AtriClip system in 2010, AtriCure has continued to expand the device’s capabilities, most recently with the AtriClip PRO2 device launched in 2016.  

The AtriClip System is cleared by the U.S. Food and Drug Administration (FDA) with an indication for occlusion of the left atrial appendage, under direct visualization, in conjunction with other open cardiac surgical procedures. The clearance resulted in part from the successful EXCLUDE trial (NCT00779857), which showed the LAA was closed successfully with the AtriClip device in 98.4 percent of patients, with no device-related mortality.4

In February of 2016, AtriCure enrolled the first patient in the ATLAS (AtriClip Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures) clinical study. This observational study can enroll up to 2,000 patients without a documented pre-operative history of Afib but who present with significant risk factors for developing post-operative AF (POAF) and also have significant risk factors for bleeding on commonly prescribed medication to decrease the risk of Afib-related stroke.

This randomized prospective study (AtriClip vs. no AtriClip) will evaluate resource utilization, including hospital length of stay, emergency room and/or hospital re-admissions, and costs associated with specific adverse events that may be related to atrial fibrillation through 365 days post index procedure.

For more information: www.atricure.com

References

1. Jeff S. Healey, MD, Eugene Crystal, MD, Andrew Lamy, et al. “Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.” American Heart Journal. 2005 Aug; 150:288-93.
2. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009 Feb 3; 119(4):606-18.
3. Marini C, De Santis F, Sacco S, et al. “Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.” Stroke. 2005 Jun; 36 (6):1115-9.
4. Data on file at AtriCure. IDE G080095, EXCLUDE study.

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation| January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation| January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation| December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation| November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation| October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init